HC Wainwright Has Negative Outlook of AVDL FY2027 Earnings

Avadel Pharmaceuticals plc (NASDAQ:AVDL) – HC Wainwright cut their FY2027 EPS estimates for Avadel Pharmaceuticals in a research report issued on Wednesday, November 13th. HC Wainwright analyst O. Livnat now anticipates that the company will earn $1.67 per share for the year, down from their previous estimate of $1.74. HC Wainwright has a “Buy” rating and a $25.00 price target on the stock. The consensus estimate for Avadel Pharmaceuticals’ current full-year earnings is ($0.50) per share. HC Wainwright also issued estimates for Avadel Pharmaceuticals’ FY2028 earnings at $1.88 EPS.

AVDL has been the subject of several other research reports. Needham & Company LLC reissued a “buy” rating and issued a $22.00 price objective on shares of Avadel Pharmaceuticals in a report on Tuesday. Oppenheimer boosted their price target on shares of Avadel Pharmaceuticals from $29.00 to $30.00 and gave the company an “outperform” rating in a research report on Thursday, October 31st. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $24.43.

Avadel Pharmaceuticals Stock Performance

NASDAQ:AVDL traded down $0.30 during trading hours on Thursday, reaching $11.72. The stock had a trading volume of 81,709 shares, compared to its average volume of 1,176,766. The stock has a market cap of $1.13 billion, a P/E ratio of -15.21 and a beta of 1.47. The stock has a 50 day simple moving average of $13.62 and a 200 day simple moving average of $15.09. Avadel Pharmaceuticals has a 12-month low of $10.39 and a 12-month high of $19.09.

Avadel Pharmaceuticals (NASDAQ:AVDL) last released its earnings results on Tuesday, November 12th. The company reported ($0.03) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.03. Avadel Pharmaceuticals had a negative net margin of 52.53% and a negative return on equity of 92.12%. The firm had revenue of $50.00 million during the quarter, compared to the consensus estimate of $48.43 million. During the same period in the prior year, the firm earned ($0.41) EPS. The company’s revenue was up 624.6% compared to the same quarter last year.

Institutional Trading of Avadel Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of AVDL. FMR LLC purchased a new stake in shares of Avadel Pharmaceuticals in the third quarter worth $31,000. Amalgamated Bank purchased a new stake in shares of Avadel Pharmaceuticals in the 2nd quarter valued at about $45,000. Quarry LP bought a new stake in shares of Avadel Pharmaceuticals during the 2nd quarter valued at about $63,000. BNP Paribas Financial Markets grew its holdings in shares of Avadel Pharmaceuticals by 60.5% during the first quarter. BNP Paribas Financial Markets now owns 4,469 shares of the company’s stock worth $75,000 after purchasing an additional 1,685 shares in the last quarter. Finally, Advisors Asset Management Inc. increased its position in shares of Avadel Pharmaceuticals by 56.1% in the third quarter. Advisors Asset Management Inc. now owns 7,921 shares of the company’s stock worth $104,000 after purchasing an additional 2,846 shares during the last quarter. 69.19% of the stock is currently owned by hedge funds and other institutional investors.

Avadel Pharmaceuticals Company Profile

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017.